Clinical Trials Browser

Phase 2/3 × INDUSTRY × omburtamab I-131 × Clear all

NCT03275402 2024-02-13

131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases

Phase 2/3 Terminated

52 enrolled 11 charts

Neuroblastoma, Meningeal Carcinomatosis